|
Iron Metabolism in Ts65Dn mice, a Model of Down syndrome |
1R15AG077421-01 |
|
NIA |
2022 |
|
Restoration of proteostasis to address co-occurring conditions in Down Syndrome |
1RF1AG078969-01 |
|
NIA |
2022 |
|
Cell and Network Disruptions and Associated Pathogenenesis in Tauopathy and Down Syndrome |
3R01AG064579-03S1 |
|
NIA |
2022 |
|
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease |
5R01AG055523-05 |
|
NIA |
2022 |
|
Cell and Network Disruptions and Associated Pathogenenesis in Tauopathy and Down Syndrome |
5R01AG064579-03 |
|
NIA |
2022 |
|
Plasticity of cortical circuits in health, aging, and Alzheimer's disease |
1 F99 AG073558-01 |
|
NIA |
2021 |
|
A Human iPSC-Based Chimeric Mouse Model of Alzheimers Disease in Down Syndrome |
1 R01 AG073779-01 |
|
NIA |
2021 |
|
Targeting protein synthesis dysregulation in Down syndrome-associated cognitive impairment with aging |
1 R01 AG073823-01 |
|
NIA |
2021 |
|
Investigating the Effects of APOE Genotype on AD Pathology in a Novel AD Mouse Model |
1 R21 AG074308-01 |
|
NIA |
2021 |
|
Development and Validation of a Marmoset Model of Late-Onset Alzheimer Disease Based on Tau Seeding |
1 R24 AG073190-01 |
|
NIA |
2021 |